-
Something wrong with this record ?
Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients
O. Bartošová, C. Bonnet, O. Ulmanová, M. Šíma, F. Perlík, E. Růžička, O. Slanař,
Language English Country Austria
Document type Journal Article
Grant support
204022
UNCE - International
Q25
Progres - International
- MeSH
- Antiparkinson Agents administration & dosage MeSH
- Adult MeSH
- Levodopa administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Parkinson Disease drug therapy MeSH
- Pupil drug effects MeSH
- Aged MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupilla diameter may thus serve as an indirect measure of peripheral pharmacokinetics of L-DOPA and dopamine. The aim of this study is to evaluate the effect of L-DOPA dosage on pupillometric parameters in Parkinson's disease (PD) patients. Sixteen PD patients and 14 healthy control subjects (CS) were studied. The statistical analysis revealed significant differences between CS and PD patients for the mean maximum and minimum pupil diameters (p = 0.017, p = 0.028, respectively), with higher values found in PD. Moreover, a significant dose-response relationship was found between the maximum pupil diameter and both the morning L-DOPA dose (R 2 = 0.78) and the total daily L-DOPA dose (R 2 = 0.93). A sigmoid-shaped curve best describes the dose-response relationship, with a ceiling effect at about 400 mg L-DOPA daily dose. In conclusion, measuring pupillometric parameters represents a sensitive tool for non-invasive evaluation of the peripheral effect of L-DOPA, especially with daily doses below 400 mg L-DOPA.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045576
- 003
- CZ-PrNML
- 005
- 20200115091006.0
- 007
- ta
- 008
- 200109s2018 au f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00702-017-1829-1 $2 doi
- 035 __
- $a (PubMed)29255941
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a au
- 100 1_
- $a Bartošová, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. olga.matouskova@lf1.cuni.cz.
- 245 10
- $a Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients / $c O. Bartošová, C. Bonnet, O. Ulmanová, M. Šíma, F. Perlík, E. Růžička, O. Slanař,
- 520 9_
- $a Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupilla diameter may thus serve as an indirect measure of peripheral pharmacokinetics of L-DOPA and dopamine. The aim of this study is to evaluate the effect of L-DOPA dosage on pupillometric parameters in Parkinson's disease (PD) patients. Sixteen PD patients and 14 healthy control subjects (CS) were studied. The statistical analysis revealed significant differences between CS and PD patients for the mean maximum and minimum pupil diameters (p = 0.017, p = 0.028, respectively), with higher values found in PD. Moreover, a significant dose-response relationship was found between the maximum pupil diameter and both the morning L-DOPA dose (R 2 = 0.78) and the total daily L-DOPA dose (R 2 = 0.93). A sigmoid-shaped curve best describes the dose-response relationship, with a ceiling effect at about 400 mg L-DOPA daily dose. In conclusion, measuring pupillometric parameters represents a sensitive tool for non-invasive evaluation of the peripheral effect of L-DOPA, especially with daily doses below 400 mg L-DOPA.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antiparkinsonika $x aplikace a dávkování $7 D000978
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a levodopa $x aplikace a dávkování $7 D007980
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Parkinsonova nemoc $x farmakoterapie $7 D010300
- 650 _2
- $a pupila $x účinky léků $7 D011680
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bonnet, C $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Ulmanová, O $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Šíma, M $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Perlík, F $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Růžička, E $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Slanař, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00010058 $t Journal of neural transmission (Vienna, Austria : 1996) $x 1435-1463 $g Roč. 125, č. 4 (2018), s. 699-703
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29255941 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200115091339 $b ABA008
- 999 __
- $a ok $b bmc $g 1483844 $s 1084249
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 125 $c 4 $d 699-703 $e 20171219 $i 1435-1463 $m Journal of neural transmission $n J Neural Transm $x MED00010058
- GRA __
- $a 204022 $p UNCE $2 International
- GRA __
- $a Q25 $p Progres $2 International
- LZP __
- $a Pubmed-20200109